JP7857044B2 - シプロフロキサシン及びセレコキシブを含む組成物 - Google Patents

シプロフロキサシン及びセレコキシブを含む組成物

Info

Publication number
JP7857044B2
JP7857044B2 JP2024523514A JP2024523514A JP7857044B2 JP 7857044 B2 JP7857044 B2 JP 7857044B2 JP 2024523514 A JP2024523514 A JP 2024523514A JP 2024523514 A JP2024523514 A JP 2024523514A JP 7857044 B2 JP7857044 B2 JP 7857044B2
Authority
JP
Japan
Prior art keywords
ciprofloxacin
celecoxib
tablet
weight
hydroxypropyl methylcellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024523514A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539116A5 (enExample
JP2024539116A (ja
Inventor
ヌーン，アロン ベン
スターリング，ジェフリー
ヤコビー－ゼヴィ，オロン
ヴェレッド，シャロン コーエン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurosense Therapeutics Ltd
Original Assignee
Neurosense Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosense Therapeutics Ltd filed Critical Neurosense Therapeutics Ltd
Publication of JP2024539116A publication Critical patent/JP2024539116A/ja
Publication of JP2024539116A5 publication Critical patent/JP2024539116A5/ja
Application granted granted Critical
Publication of JP7857044B2 publication Critical patent/JP7857044B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2024523514A 2021-10-19 2022-10-18 シプロフロキサシン及びセレコキシブを含む組成物 Active JP7857044B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163257130P 2021-10-19 2021-10-19
US63/257,130 2021-10-19
PCT/IL2022/051096 WO2023067592A1 (en) 2021-10-19 2022-10-18 Compositions comprising ciprofloxacin and celecoxib

Publications (3)

Publication Number Publication Date
JP2024539116A JP2024539116A (ja) 2024-10-28
JP2024539116A5 JP2024539116A5 (enExample) 2025-10-10
JP7857044B2 true JP7857044B2 (ja) 2026-05-12

Family

ID=85982158

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024523514A Active JP7857044B2 (ja) 2021-10-19 2022-10-18 シプロフロキサシン及びセレコキシブを含む組成物

Country Status (9)

Country Link
US (1) US12097185B2 (enExample)
EP (1) EP4419099A4 (enExample)
JP (1) JP7857044B2 (enExample)
KR (1) KR20240090519A (enExample)
CN (1) CN118369097A (enExample)
AU (1) AU2022370513B2 (enExample)
CA (1) CA3235348A1 (enExample)
IL (1) IL312274A (enExample)
WO (1) WO2023067592A1 (enExample)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020527542A (ja) 2017-06-20 2020-09-10 ニューロセンス セラピューティックス リミテッドＮｅｕｒｏｓｅｎｓｅ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｔｄ． 抗炎症剤及びダイサー活性化剤を含む神経疾患治療用組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
US12527768B2 (en) * 2017-06-20 2026-01-20 Neurosense Therapeutics Ltd. Compositions comprising an anti-inflammatory drug and a dicer activator for use in the treatment of neuronal diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020527542A (ja) 2017-06-20 2020-09-10 ニューロセンス セラピューティックス リミテッドＮｅｕｒｏｓｅｎｓｅ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｔｄ． 抗炎症剤及びダイサー活性化剤を含む神経疾患治療用組成物

Also Published As

Publication number Publication date
US20230120880A1 (en) 2023-04-20
EP4419099A1 (en) 2024-08-28
US12097185B2 (en) 2024-09-24
IL312274A (en) 2024-06-01
CA3235348A1 (en) 2023-04-27
AU2022370513A1 (en) 2024-05-16
CN118369097A (zh) 2024-07-19
EP4419099A4 (en) 2025-09-24
AU2022370513B2 (en) 2025-09-25
KR20240090519A (ko) 2024-06-21
JP2024539116A (ja) 2024-10-28
WO2023067592A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
EP1441713B1 (en) Modified release tamsulosin tablets
RU2376988C2 (ru) Фармацевтические композиции замедленного высвобождения, содержащие аплиндор и его производные
US11590122B2 (en) Pharmaceutical compositions of cabozantinib
CN107666914A (zh) 帕博西尼的固体剂型
JP2000229888A (ja) マトリックス制御放出デバイス
TW201442742A (zh) 祛鐵斯若（ｄｅｆｅｒａｓｉｒｏｘ）之口服配方
WO2006082523A2 (en) Pharmaceutical sustained release composition of metformin
JP2001524131A (ja) 安定な経口医薬品剤形
AU2007338359A1 (en) Pharmaceutical formulation comprising neurokinin antagonist
JP2013532651A (ja) シロドシンと塩基性コポリマーとの混合物を含む経口投与用医薬品
JP2015506337A (ja) 新規配合剤
US20130344148A1 (en) Oral Composition
JPH05246861A (ja) ポリカルボフィルカルシウム含有製剤
JP2022534159A (ja) 微細化した固形メラトニン組成物
WO2009027786A2 (en) Matrix dosage forms of varenicline
CA3163555A1 (en) Methotrexate dosage form
KR101761983B1 (ko) 구강내 속붕해 필름 조성물 및 그 제조방법
JP2007512287A (ja) 有機化合物を含む組成物
AU2022370513B2 (en) Compositions comprising ciprofloxacin and celecoxib
JP2006507298A (ja) 経口持続放出型錠剤、ならびにその製造法および使用法
HK40113418A (zh) 包含环丙沙星和塞来昔布的组合物
BR112024007727B1 (pt) Composições que compreendem ciprofloxacina e celecoxibe
EP1448171A2 (en) Pharmaceutical formulation comprising more than 15% tamoxifen
KR101428149B1 (ko) 이매티닙메실산염 함유 과립, 이를 포함하는 경구용 속방성 정제 조성물 및 그것의 제조방법
CN119278030A (zh) 一种双重释放制剂及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251002

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20251002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260323

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260407

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260417